JNJ
33
-2
TRV
40
-2
URI
43
-2
BEN
45
-4
IP
57
3
CTSH
52
-4
KO
46
4
HD
50
-2
QRVO
13
4
MSI
50
-8
RL
72
-3
IFF
48
-2
DTE
45
-2
LB
1
-8
URBN
63
-7
PH
64
-2
C
58
-2
FSLR
58
9
BLK
60
-3
KSS
24
-2
JNJ
33
-2
TRV
40
-2
URI
43
-2
BEN
45
-4
IP
57
3
CTSH
52
-4
KO
46
4
HD
50
-2
QRVO
13
4
MSI
50
-8
RL
72
-3
IFF
48
-2
DTE
45
-2
LB
1
-8
URBN
63
-7
PH
64
-2
C
58
-2
FSLR
58
9
BLK
60
-3
KSS
24
-2
Financhill
Back

Spyre Therapeutics 10K Form

Sell
28

SYRE
Spyre Therapeutics

Last Price:
23.94
Seasonality Move:
4.87%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive SYRE News And Ratings

See the #1 stock for the next 7 days that we like better than SYRE

SYRE Financial Statistics

Sales & Book Value

Annual Sales: $886K
Cash Flow: $-29.42M
Price / Cash Flow: 0
Annual Sales: $3.34
Price / Book: 8.18

Profitability

EPS (TTM): -4.12220
Net Income (TTM): $-214.9M
Gross Margin: --
Return on Equity: 0%
Return on Assets: 0%

Spyre Therapeutics Earnings Forecast

Key Spyre Therapeutics Financial Ratios

  • The Research & Development expenses have been 10,102.03% of Revenue.
  • The Net Earning history of SYRE is -38,238.15% of Total Revenues.
  • Per Share Earnings over the last 10 years have been positive in 6 years.

Spyre Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: SYRE
Website: spyre.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

SYRE Technical Analysis vs Fundamental Analysis

Sell
28
Spyre Therapeutics (SYRE) is a Sell

Is Spyre Therapeutics a Buy or a Sell?